RBC Europe’s Rigel Pharmaceuticals RIGL Stock Holding History

RBC Europe’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-150	Closed	-$5.45K	–	1033
2021 Q3	$5.45K	Hold	150	–	–	﹤0.01%	1031
2021 Q2	$6.51K	Hold	150	–	–	﹤0.01%	1022
2021 Q1	$5.13K	Hold	150	–	–	﹤0.01%	1001
2020 Q4	$5.25K	Hold	150	–	–	﹤0.01%	966
2020 Q3	$3.6K	Hold	150	–	–	﹤0.01%	931
2020 Q2	$2.75K	Hold	150	–	–	﹤0.01%	928
2020 Q1	$2.34K	Hold	150	–	–	﹤0.01%	901
2019 Q4	$3.21K	Hold	150	–	–	﹤0.01%	930
2019 Q3	$2.81K	Hold	150	–	–	﹤0.01%	941
2019 Q2	$3.92K	Hold	150	–	–	﹤0.01%	939
2019 Q1	$3.85K	Hold	150	–	–	﹤0.01%	952
2018 Q4	$3.45K	Hold	150	–	–	﹤0.01%	955
2018 Q3	$4.82K	Hold	150	–	–	﹤0.01%	967
2018 Q2	$4.25K	Hold	150	–	–	﹤0.01%	987
2018 Q1	$5.31K	Hold	150	–	–	﹤0.01%	935
2017 Q4	$5.82K	Hold	150	–	–	﹤0.01%	926
2017 Q3	$3.81K	Buy	+150	New	+$3.65K	﹤0.01%	995

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

RBC Europe's RIGL Position: Q4 2021 in Review

RBC Europe sold out of Rigel Pharmaceuticals (RIGL) in Q4 2021, closing a stake of 150 shares — an estimated $5.45K sold.

RBC Europe first reported a position in RIGL in Q3 2017 and held it in 17 quarters. The position peaked at $6.51K in Q2 2021. 162 funds tracked by Wall St. Rank hold RIGL as of Q4 2021.

RBC Europe reported no remaining Rigel Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
RBC Europe sold 150 Rigel Pharmaceuticals shares in Q4 2021, an estimated $5.45K.
RBC Europe first reported a position in Rigel Pharmaceuticals in Q3 2017 and held it in 17 quarters.
RBC Europe's Rigel Pharmaceuticals position peaked at $6.51K in Q2 2021.
162 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.